Shares of 10 companies were hit hard on Thursday, bucking a mostly optimistic broader market, as investor sentiment was dragged down by disappointing earnings performances and loss of key partnerships.
The Dow Jones was the sole decliner during the day, losing 0.28 percent in its valuation. In contrast, the S&P 500 and Nasdaq Composite both ended firmer, rallying by 0.36 percent and 0.51 percent, respectively.
This article details the reasons behind the 10 companies’ lackluster performance.
To come up with Thursday’s worst performers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.
Stock market data on a laptop screen. Photo by Alesia Kozik on Pexels
10. Under Armour Inc. (NYSE:UAA)
Under Armour saw its share prices drop by 7.77 percent on Thursday to close at $7.6 apiece after posting disappointing earnings results for the third quarter of fiscal year 2025.
In an earnings presentation, the company’s net income for the quarter ending December 2024 fell by 99 percent to $1.2 million from the $110.75 million registered in the same period a year ago as net revenues dropped 6 percent to $1.4 billion versus $1.49 billion year-on-year.
In the first nine months alone, Under Armour swung to a net loss of $133.8 million versus a $225-million net profit in the same period year-on-year as net revenues declined by 8.9 percent to $3.98 billion from $4.37 billion.
By country segment, only the Europe, Middle East, and Africa (EMEA) region registered strength, with net revenues for the quarter and nine months up by 4.9 percent and 1.3 percent, respectively.
Net revenues from Latin America fell by 15.5 percent for the quarter, as well as with North America, by 7.8 percent, and Asia Pacific, by 5.1 percent.
9. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)
Recursion Pharmaceuticals snapped a three-day winning streak on Thursday, falling 8.59 percent to close at $7.24 apiece as investors resorted to profit-taking while repositioning their portfolios ahead of the release of its fourth-quarter earnings performance.
In recent news, Recursion Pharmaceuticals announced favorable efficacy data in the second phase trial for its REC-994, a lead AI-derived candidate aimed at treating a fatal brain disease called cerebral cavernous malformation.
CCM is characterized by an enlargement and irregularity in the shape of small blood vessels in the brain. The vessels can alter blood flow and place patients at risk for seizures, headaches, progressive neurological deficits, and potentially fatal hemorrhagic stroke.
At present, CCM treatment is limited only to surgery and radiation therapy treatments.
8. New Fortress Energy Inc. (NASDAQ:NFE)
New Fortress fell for a fifth consecutive day on Thursday, dropping 9.24 percent to finish at $12.57 apiece as investor sentiment was weighed down by twin news that a shareholder law firm is investigating the company over issues about their revenue outlook, while also earning a credit rating downgrade from an investment bank.
On Thursday, law firm Johnson Fistel LLP said it launched an investigation into New Fortress Energy following a class action lawsuit over claims that it created the false impression that it possessed reliable information on its projected revenue growth outlook, while simultaneously downplaying the risks associated with its Fast Liquefied Natural Gas projects.
Meanwhile, the company earned a downgraded issuer credit rating from “B+” to “B” from S&P Global Ratings over concerns about its liquidity and high leverage.
The downgrade also reflects S&P’s outlook on the company’s financial health.
7. Hologic Inc. (NASDAQ:HOLX)
Hologic dropped its share prices on Thursday by 10.10 percent to end at $65.45 apiece amid disappointing earnings results in the first quarter of fiscal year 2025.
In a statement, Hologic said net income in the quarter fell by 18 percent to $201 million from $246.5 million, while revenues were flat at $1.02 billion versus $1.01 billion.
Meanwhile, the company achieved GAAP earnings per share of 87 cents and non-GAAP EPS of $1.03, reaching the high end of guidance.
For the full year, Hologic said it expects revenues to decline to between $4.05 billion and $4.1 billion, but maintained its non-GAAP EPS guidance of $4.25 to $4.35.
Last month, Hologic completed the acquisition of Gynesonics for approximately $350 million.
Hologic is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.
6. Roblox Corp. (NYSE:RBLX)
Shares of Roblox tumbled 11.15 percent on Thursday to end at $67.12 apiece as investor sentiment was dampened by weak outlook guidance, despite improvements in its earnings performance last year.
For the full year 2025, Roblox expects revenues to settle between $4.25 billion and $4.34 billion, as well as a consolidated net loss between $995 million and $1.07 billion.
In the fourth quarter of 2024, Roblox was able to trim its net loss attributable to shareholders by 32 percent to $219.6 million from the $323.7 million registered in the same period a year earlier.
Net loss attributable to shareholders for the full year 2024 also narrowed by 19 percent to $935 million from $1.15 billion year-on-year.
Meanwhile, revenues for the quarter increased by 31.7 percent to $988 million from $749.94 million year-on-year. Revenues for the full year jumped by 28 percent to $3.6 billion from $2.8 billion.
5. Venture Global Inc. (NYSE:VG)
Venture Global dropped its share prices for a third day on Thursday, by 11.18 percent to finish at $17.48 apiece, following news that TotalEnergies rejected opportunities to become a long-term customer of Venture Global, citing a lack of trust.
TotalEnergies CEO Patrick Pouyanne told Reuters on Wednesday that he was approached by Venture Global to see if the company would be interested in a long-term supply contract for liquefied natural gas from the Calcasieu Pass terminal in Louisiana, but rejected “because of what they are doing.”
Venture Global is facing legal challenges from huge clients namely BP and Shell for the delays in supply contracts as it commissions its projects.
Meanwhile, Venture Global said it was surprised by Pouyanne’s comments, but said that they continue to honor its contracts and execute the construction of its facilities safely and at a record pace.
4. Eldorado Gold Corp. (NYSE:EGO)
Eldorado Gold saw its share prices fall by 11.27 percent on Thursday to close at $14.01 apiece as investor sentiment was dragged down by announcements of additional capital outlays and delays in its Skouries copper-gold project.
In a statement released to the media on Thursday, Eldorado said it was hiking the project cost of the Skouries project by $143 million, or 15.5 percent more, to a total of $1.06 billion.
In addition, the company expects to complete additional pre-commercial production mining and has accelerated the purchase of higher capacity mobile mining equipment—originally expected to be purchased post-commercial production—resulting in $154 million of accelerated operational capital prior to commercial production.
Eldorado Gold said the first production at Skouries is now expected in the first quarter of 2026, followed by commercial production in mid-2026.
Despite revised schedule and cost estimates, Eldorado said that it would maintain the number of workforce at approximately 1,300 workers through the peak of construction activities.
3. Symbotic Inc. (NASDAQ:SYM)
Shares of Symbotic Inc. declined by 15.94 percent to end Thursday’s trading at $25.99 apiece following disappointing profit performance in the first quarter of fiscal year 2025.
In its latest earnings release, Symbotic registered a 22.5-percent wider net loss attributable to shareholders at $3.4 million versus the $2.8 million registered in the same period a year earlier, despite revenues increasing by 35 percent to $487 million from $360 million.
Net loss alone narrowed by 3 percent to $18.5 million from $19.07 million year-on-year.
For the second quarter of fiscal year 2025, Symbotic said it expects revenue to settle between $510 million and $530 million, while adjusted EBITDA was projected to end between $26 million to $30 million.
“Looking forward to the fiscal second quarter of 2025, we expect another quarter of at least 30 percent year-over-year revenue growth with expanding margins,” said Symbotic Chief Financial Officer Carol Hibbard.
2. Helmerich & Payne (NYSE:HP)
Shares of Helmerich & Payne fell 16.48 percent on Thursday to close at $27.72 apiece after reporting disappointing earnings performance in the first quarter of fiscal year 2025.
In a filing, Helmerich & Payne said net income in the quarter declined by 42 percent to $54.77 million from the $95.17 million registered in the same period a year earlier as revenues ended flat at $677 million.
For the second quarter of the fiscal year, Helmerich & Payne expects gross capital expenditures to settle between $360 million to $395 million.
For the full fiscal year, general and administrative taxes will continue to take up a huge chunk of its expenses at $280 million, while costs for research and development were projected to settle at $32 million.
Cash taxes to be paid were also targeted at approximately $190 million to $240 million.
1. Skyworks Solutions Inc. (NASDAQ:SWKS)
Shares of Skyworks fell by nearly 25 percent on Thursday to end at $65.6 apiece after technology giant Apple Inc. announced that it would reduce its reliance on Skyworks’ semiconductors for components in the upcoming iPhone 17.
According to Skyworks’ Chief Finance Officer Kris Sennesael, its content share in the new iPhone is expected to decline by up to 25 percent despite securing multiple sockets, including highly integrated RF modules.
According to the company, Apple accounted for 72 percent of its revenues in the last quarter.
Following the announcement, several investment banking firms downgraded Skyworks’ rating.
Analysts from Stifel said they slashed their stock rating for the company from “buy” to “hold,” while Mizuho analysts said they cut their rating for the company from “outperform” to “neutral,” citing continued headwinds through at least the iPhone 18 launch and limited near-term catalysts.
While we acknowledge the potential of SWKS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than SWKS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
